European Journal of Cancer
Volume 41, Issue 11 , Pages 1515-1527 , July 2005

Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer

  • Angelika M. Burger

      Affiliations

    • Laboratory of Molecular Pathology, Department of Anatomic Pathology and Division of Molecular and Cellular Biology, S-224, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ont., Canada M4N 3M5
    • Corresponding Author InformationCorresponding authors. Tel.: +416 480 4011; fax: +416-480 4271.
    • ,
  • Brian Leyland-Jones

      Affiliations

    • Department of Oncology, McGill University, Montreal, Que., Canada H2W 1S6
    • ,
  • Kris Banerjee

      Affiliations

    • Department of Oncology, McGill University, Montreal, Que., Canada H2W 1S6
    • ,
  • Demetri D. Spyropoulos

      Affiliations

    • Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Hollingshead Cancer Center, Charleston, SC 29425-2213, USA
    • ,
  • Arun K. Seth

      Affiliations

    • Laboratory of Molecular Pathology, Department of Anatomic Pathology and Division of Molecular and Cellular Biology, S-224, Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ont., Canada M4N 3M5
    • Department of Laboratory Medicine and Pathobiology and CIHR Group in Matrix Dynamics, University of Toronto, Toronto, Ont., Canada M4N 3M5
    • Corresponding Author InformationCorresponding authors. Tel.: +416 480 4011; fax: +416-480 4271.

Received 8 January 2005 ,Revised 11 April 2005 ,Accepted 18 April 2005.

References 

  1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–518
  2. Pollak MN. Insulin-like growth factors and neoplasia. Novartis Found Symp. 2004;262:84–98discussion 98–107, 265–268
  3. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20:761–787
  4. Sepp-Lorenzino L. Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat. 1998;47:235–253
  5. Zapf J. Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol/Eur Fed Endocr Soc. 1995;132:645–654
  6. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996;76:1005–1026
  7. Rajah R, Khare A, Lee PD, et al. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol. 1999;163:487–494
  8. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–854
  9. Vilmos P, Gaudenz K, Hegedus Z, et al. The Twisted gastrulation family of proteins, together with the IGFBP and CCN families, comprise the TIC superfamily of cysteine rich secreted factors. Mol Pathol. 2001;54:317–323
  10. Upton Z, Chan SJ, Steiner DF, et al. Evolution of insulin-like growth factor binding proteins. Growth Regul. 1993;3:29–32
  11. Collet C, Candy J. How many insulin-like growth factor binding proteins?. Mol Cell Endocrinol. 1998;139:1–6
  12. Kim HS, Nagalla SR, Oh Y, et al. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA. 1997;94:12981–12986
  13. Fowlkes JL, Thrailkill KM, George-Nascimento C, et al. Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology. 1997;138:2280–2285
  14. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64:665–671
  15. Manes S, Llorente M, Lacalle RA, et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 1999;274:6935–6945
  16. Clemmons DR, Camacho-Hubner C, Coronado E, et al. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990;127:2679–2686
  17. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res. 1991;3(4):243–266
  18. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Hormone Res. 1994;42:140–144
  19. Barreca A, Artini PG, Cesarone A, et al. Interrelationships between follicle stimulating hormone and the growth hormone – insulin-like growth factor – IGF-binding proteins axes in human granulosa cells in culture. J Endocrinol Invest. 1996;19:35–42
  20. Li YM, Schacher DH, Liu Q, et al. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology. 1997;138:362–368
  21. Schedlich LJ, Young TF, Firth SM, et al. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem. 1998;273:18347–18352
  22. Jaques G, Noll K, Wegmann B, et al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology. 1997;138:1767–1770
  23. Li W, Fawcett J, Widmer HR, et al. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology. 1997;138:1763–1766
  24. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol. 2001;54:145–148
  25. Schedlich LJ, Le Page SL, Firth SM, et al. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem. 2000;275:23462–23470
  26. Liu B, Lee HY, Weinzimer SA, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signalling and apoptosis. J Biol Chem. 2000;275:33607–33613
  27. Gajewska M, Motyl T. IGF-binding proteins mediate TGF-beta1-induced apoptosis in bovine mammary epithelial BME-UV1 cells. Comp Biochem Physiol C Toxicol Pharmacol. 2004;139:65–75
  28. Schmid C, Ghirlanda-Keller C, Zapf J. Effects of IGF-I and -II, IGF binding protein-3 (IGFBP-3), and transforming growth factor-beta (TGF-beta) on growth and apoptosis of human osteosarcoma Saos-2/B-10 cells: lack of IGF-independent IGFBP-3 effects. Eur J Endocrinol. 2001;145:213–221
  29. Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem. 1999;274:6711–6717
  30. Kuemmerle JF, Murthy KS, Bowers JG. IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G795–G802
  31. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem. 1993;268:26045–26048
  32. Leal SM, Liu Q, Huang SS, et al. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem. 1997;272:20572–20576
  33. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272:12181–12188
  34. Yamanaka Y, Fowlkes JL, Wilson EM, et al. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology. 1999;140:1319–1328
  35. Butt AJ, Firth SM, King MA, et al. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275:39174–39181
  36. Sadowski T, Dietrich S, Koschinsky F, et al. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell. 2003;14:4569–4580
  37. Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64:665–671
  38. Mochizuki S, Shimoda M, Shiomi T, et al. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun. 2004;315:79–84
  39. Mishra S, Murphy LJ. Phosphorylation of insulin-like growth factor (IGF) binding protein-3 by breast cancer cell membranes enhances IGF-I binding. Endocrinology. 2003;144:4042–4050
  40. Schedlich LJ, Nilsen T, John AP, et al. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology. 2003;144:1984–1993
  41. Firth SM, Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol. 1999;160:379–387
  42. Murphy M, Pykett MJ, Harnish P, et al. Identification and characterization of genes differentially expressed in meningiomas. Cell Growth Differ. 1993;9:715–722
  43. Oh Y, Nagalla SR, Yamanaka Y, et al. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996;271:30322–30325
  44. Akaogi K, Okabe Y, Funahashi K, et al. Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun. 1994;198:1046–1053
  45. Akaogi K, Okabe Y, Sato J, et al. Specific accumulation of tumour-derived adhesion factor in tumour blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1996;93:8384–8389
  46. Sato J, Hasegawa S, Akaogi K, et al. Identification of cell-binding site of angiomodulin (AGM/TAF/Mac25) that interacts with heparan sulfates on cell surface. J Cell Biochem. 1999;75:187–195
  47. Yamauchi T, Umeda F, Masakado M, et al. Purification and molecular cloning of prostacyclin-stimulating factor from serum-free conditioned medium of human diploid fibroblast cells. Biochem J. 1994;303(Pt 2):591–598
  48. Burger A, Li H, Zhang XK, et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene. 1998;16:327–333
  49. Yamanaka Y, Wilson EM, Rosenfeld RG, et al. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997;272:30729–30734
  50. Kato MV. A secreted tumour-suppressor, mac25, with activin-binding activity. Mol Med. 2000;6:126–135
  51. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4:157–166
  52. Jeruss JS, Sturgis CD, Rademaker AW, et al. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res. 2003;63:3783–3790
  53. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumour endothelium. Science. 2000;289:1197–1202
  54. Fowlkes JL, Thrailkill KM, Serra DM, et al. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res. 1995;6:255–263
  55. Ahmed S, Yamamoto K, Sato Y, et al. Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/mac25) modulates its biological activity. Biochem Biophys Res Commun. 2003;310:612–618
  56. Komatsu S, Okazaki Y, Tateno M, et al. Methylation and downregulated expression of mac25/insulin-like growth factor binding protein-7 is associated with liver tumourigenesis in SV40T/t antigen transgenic mice, screened by restriction landmark genomic scanning for methylation (RLGS-M). Biochem Biophys Res Commun. 2000;267:109–117
  57. Kanemitsu N, Kato MV, Miki T, et al. Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun. 2000;279:251–257
  58. Burger AM, Zhang X, Li H, et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene. 1998;16:2459–2467
  59. Swisshelm K, Ryan K, Tsuchiya K, et al. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA. 1995;92:4472–4476
  60. Lopez-Bermejo A, Buckway CK, Devi GR, et al. Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology. 2000;141:4072–4080
  61. Lopez-Bermejo A, Khosravi J, Corless CL, et al. Generation of anti-insulin-like growth factor-binding protein-related protein 1 (IGFBP-rP1/MAC25) monoclonal antibodies and immunoassay: quantification of IGFBP-rP1 in human serum and distribution in human fluids and tissues. J Clin Endocrinol Metab. 2003;88:3401–3408
  62. Degeorges A, Wang F, Frierson HF, et al. Distribution of IGFBP-rP1 in normal human tissues. J Histochem Cytochem. 2000;48:747–754
  63. Dominguez F, Avila S, Cervero A, et al. A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein 1 as a new gene implicated in human endometrial receptivity. J Clin Endocrinol Metab. 2003;88:1849–1857
  64. Wandji SA, Gadsby JE, Barber JA, et al. Messenger ribonucleic acids for MAC25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis. Endocrinology. 2000;141:2648–2657
  65. Casey OM, Fitzpatrick R, McInerney JO, et al. Analysis of gene expression in the bovine corpus luteum through generation and characterisation of 960 ESTs. Biochim Biophys Acta. 2004;1679:10–17
  66. Kim JG, Kim MH, Kim IS, et al. Decreased expression of mac25 mRNA in uterine leiomyomata compared with adjacent myometrium. Am J Reprod Immunol. 2000;43:53–57
  67. Burger AM, Spyropoulos DD, Kahn HJ, et al. Development of an insulin-like growth factor binding protein-related protein 1 knockout mouse. Proc Amer Assoc Cancer Res. 2005;46:1080
  68. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer. 2001;8:197–209
  69. Hadsell DL, Bonnette SG. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia. 2000;5:19–30
  70. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–1353
  71. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393–1396
  72. Krajcik RA, Borofsky ND, Massardo S, et al. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1566–1573
  73. Wilson EM, Oh Y, Rosenfeld RG. Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab. 1997;82:1301–1303
  74. Burger AM, Zhang X, Seth A. Detection of novel genes that are up- (Di12) or down-regulated (T1A12) with disease progression in breast cancer. Eur J Cancer Prev. 1998;7:S29–S35
  75. Seth A, Kitching R, Landberg G, et al. Identification of genes differentially expressed in ductal carcinoma in situ and invasive breast tumours. Anticancer Res. 2003;23:2043–2052
  76. Landberg G, Östlund H, Nielsen NH, et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumours. Oncogene. 2001;20:3497–3505
  77. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990;50:48–53
  78. Baserga R. Targeting the IGF-I receptor: from rags to riches. Eur J Cancer. 2004;40:2013–2015
  79. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol. 1997;189:33–48
  80. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989;84:1418–1423
  81. Firth SM, Fanayan S, Benn D, et al. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun. 1998;246:325–329
  82. Butt AJ, Firth S, King MA, et al. Insulin-like growth factor binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem. 2000;275:39174–39181
  83. U.S. patents 5,789,547 (US). Title: Method of producing insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding. August 4, 1998. Assignee: Celtrix Pharmaceuticals, Inc. (US)-5,527,776. Title: Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF. Issued: June 18, 1996. Assignee: Celtrix Pharmaceuticals, Inc. (US).
  84. Yu Q, Jerome L, Page V, et al. Insulin-like growth factor-binding protein 3: single-agent and synergistic effects with paclitaxel in breast tumour models. Eur J Cancer. 2004;0(Suppl 2):84;[Abstract 274]
  85. Jerome L, Yu Q, Belanger S, et al. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer. In: 26th San Antonio breast cancer symposium; 2003 [Abstract # 270].
  86. Jerome L, Yu Q, Belanger S, et al. The potential utility of recombinant human IGF binding protein-3 (rhIGFBP-3) for the treatment of HER-2-positive breast cancer. Proc Am Assoc Cancer Res. 2004;45:[Abstract # 5334]
  87. Wilson HM, Birnbaum RS, Poot M, et al. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002;13:205–213
  88. Sprenger CC, Vail ME, Evans K, et al. Over-expression of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumour growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002;21:140–147
  89. Dokmanovic M, Chang BD, Fang J, et al. Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes. Cancer Biol Ther. 2002;1:24–27
  90. Pereira RC, Blanquaert F, Canalis E. Cortisol enhances the expression of mac25/insulin-like growth factor-binding protein-related protein-1 in cultured osteoblasts. Endocrinology. 1999;140:228–232
  91. Decensi A, Johansson H, Miceli R, et al. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1047–1053
  92. Nielsen TO, Andrews HN, Cheang M, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004;64:286–291
  93. Smith V, Sausville EA, Camalier RF, et al. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) to 17-allylamino-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol [in press].
  94. Schneider MR, Lahm H, Wu M, et al. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J. 2000;14:629–640
  95. Silha JV, Murphy LJ. Insights from insulin-like growth factor binding protein transgenic mice. Endocrinology. 2002;143:3711–3714
  96. Nass SJ, Davidson NE. The biology of breast cancer. Hematol Oncol Clin North Am. 1999;13:311–332

PII: S0959-8049(05)00350-3

doi: 10.1016/j.ejca.2005.04.023

European Journal of Cancer
Volume 41, Issue 11 , Pages 1515-1527 , July 2005

Article Tools

* Image Usage & Resolution